The Austrian Competition Authority accepts commitments and closes its pharmaceutical pricing investigation on the sale of a brain tumor treatment (Merck Sharp / Dohme)

KEYWORDS
Reference

Austrian Competition Authority, Merck Sharp / Dohme GmbH, Press release, 2 April 2021

On 2 April 2021, the Austrian competition authority accepted commitments and closed its case concerning pricing strategies alleged to unlawfully hinder entry by generic competitors. According to the authority’s press release, the investigated pricing strategy concerned the product Temodal (temozolomide - a treatment for brain tumors), and

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Van Bael & Bellis (Brussels)
    Belgium 26 contributions 9933 visits
  • Van Bael & Bellis (Brussels)
    Belgium 20 contributions 6709 visits
  • Van Bael & Bellis (Brussels)
    Belgium 125 contributions 34948 visits
  • Van Bael & Bellis (Brussels)
    Belgium 34 contributions 12061 visits
  • Van Bael & Bellis (Brussels)
    Belgium 35 contributions 12167 visits

Quotation

Michael Clancy, Samuel Hall, Peter L'Ecluse, Catherine Longeval, Koen T'Syen, The Austrian Competition Authority accepts commitments and closes its pharmaceutical pricing investigation on the sale of a brain tumor treatment (Merck Sharp / Dohme), 2 April 2021, e-Competitions March 2021, Art. N° 100281

Visites 623

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues